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990Objective: A lung assist device would serve an important clinical need as a bridge to transplant or destination
therapy for patients with end-stage lung disease. A new lung assist device has been developed that incorporates
a branched network of vascular channels adjacent to a gas chamber, separated by a thin, gas-permeable mem-
brane. This study investigated 2 potential gas exchange membranes within this new architecture.
Methods: Oxygen and carbon dioxide exchange within the device was tested in vitro using 3 gas-permeable
membranes. Two of the membranes, silicone only and silicone-coated microporous polymer, were plasma imper-
meable. The third, a microporous polymer, was used as a control. Gas exchange testing was done using antico-
agulated porcine blood over a range of flow rates.
Results: Oxygen and carbon dioxide transfer was demonstrated in the device and increased nearly linearly from
0.6 to 8.0 mL/min blood flow for all of the membranes. There was no significant difference in the gas transfer
between the silicone and the silicone-coated microporous polymer membranes. The transfer of oxygen and carbon
dioxide in the device was similar to existing hollow fiber oxygenators controlling for surface area.
Conclusions: The silicone and silicone-coated microporous polymer membranes both show promise as gas-
permeable membranes in a new lung assist device design. Further optimization of the device by improving the
membranes and reducing the channel diameter in the vascular network will improve gas transfer. The current de-
vice may be scaled up to function as an adult lung assist device. (J Thorac Cardiovasc Surg 2010;140:990-5)Lung assist devices have been in development for several
decades.1-4 The 2 fundamental implantation approaches for
these devices have been in an arteriovenous shunt position
principally for intensive care unit-based care of acute lung
disease5 or as an ambulatory lung assist device with abdom-
inal or intrathoracic placement in parallel to the native
lungs.6 For ambulatory lung assist devices, the goal is to de-
velop a device that can be implanted in patients to improve
their quality of life and reduce the mortality while awaiting
a lung transplant.
The central aim of this work is to explore the application
of a branched vascular network-based scaffold to create
a lung assist device that closely matches physiologic flow
and is minimally damaging to the blood while achieving sat-
isfactory gas exchange. For the past 2 decades, nearly all of
these devices have had the same basic design architecture us-
ing a porous hollow fiber oxygenator with blood flowing
outside the fibers.7 The hollow fiber design approach
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The Journal of Thoracic and Cardiovascular Surgfor gas exchange into a small cartridge. However, it is a sig-
nificant deviation from the physiologic flow in the bifurcated
vascular network of the native lung.
In an effort to develop a tissue engineered liver, it was pro-
posed8-10 that a solid organ scaffold with a preformed
vascular network would be a means of delivering needed
oxygen and nutrients to the tissue. This architectural
concept of a tissue scaffold has been successful for in vitro
development of liver tissue.11 By applying this preformed
vascularized scaffold approach, a branched vascular net-
work of microfluidic channels analogous to capillaries
were developed for a lung assist device. A gas-permeable
membrane separates the vascular channels from the adjacent
gas chamber that carries oxygen. Gas exchange occurs
across the thin membrane.
This study compared the gas exchange characteristics of
the lung assist technology with 2 different plasma imperme-
able gas-permeable membranes: silicone and silicone-coated
porous polycarbonate. The gas exchange membranes were
evaluated within the vascular network architecture to
determine the feasibility of this approach as a long-term
implantable lung assist device.MATERIALS AND METHODS
Device Architecture
The vascularized scaffold approach for a lung is composed of 3 funda-
mental components. A branched vascular network divides the blood flow
into multiple parallel microfluidic channels to create significant surface
area for gas exchange. Adjacent to the vascular network is an alveolarery c November 2010
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Schamber for the flow of oxygen analogous to the alveoli in the lungs. The
channels of the vascular network and the alveolar chamber are separated
by a thin gas-permeable membrane. This membrane allows the exchange
of oxygen and carbon dioxide between the blood and the alveolar chamber.
The vascular network and cross-section of the device are shown in Figure 1.
Vascular Network Design
The vascular network was designed to divide the flow from a single inlet
into a high density of capillary-like network with significant surface area.
The design has a single depth of 200 mm for all of the channels, and the
width of the channels varies from several millimeters at the inlets to 200
mm in the 23 capillary-like subunits of the design. The network was
designed to achieve a high density of channels across the entire surface
area and then optimized to achieve low shear stress within the capillary-
like subunits.
The vascular network design was drafted in 3 dimensions using Solid-
Works (SolidWorks Corp, Concord, Mass). Computational fluid dynamics
analysis (FloWorks, SolidWorks Corp) using a non-Newtonian blood
model was performed over a range of flow rates to determine the shear stress
and blood velocity within the channels.
Alveolar Chamber
The alveolar chamber for the device shown in Figure 1, B, consists of an
open chamber 200 mm deep with an array of posts to maintain a constant
chamber depth. The posts are 140 mm in diameter and spaced 300 mm apart
to achieve relatively unimpeded oxygen flow within the chamber.
Photolithography manufacturing was used to create silicon molds of the
vascular network and alveolar chamber. The vascular and alveolar layers
were made with traditional soft lithography techniques by casting Sylgard
184 polydimethylsiloxane (PDMS) (Dow Corning, Midland, Mich) on the
molds and heat curing at 70C for 2 hours.
Gas Exchange Membranes
Two silicone-based gas exchange membranes were developed and tested
in the device. The silicone gas exchange membranes were made by thinning
1 mL of silicone pre-polymer (MDX4-4210, USP Class VI polymer; Dow
Corning, Midland, Mich) on a plain silicon wafer using a plate spinner
(Model 100; Brewer Science, Rolla, Mo). The silicone membranes were
then cured at 70C for 30 minutes.
The porous polycarbonate membrane, used as a control, had a pore size
of 1 mm with a pore density of 1.0 3 107 pores/cm2 for a resulting 8%
porosity (GE Water & Process Technologies, Trevose, Pa). The silicone-
coated porous polycarbonate membranes were made by spin coating the
porous polycarbonate membranes with the silicone pre-polymer using
a plate spinner at 3000 rpm for 15 minutes. The silicone was then cured
at 70C for 30 minutes.
The gas exchange membranes were bonded between the vascular and al-
veolar chambers by applying a thin layer of PDMS pre-polymer to the top of
the layers and then joining the respective layers to opposite sides of the
membrane and heat curing the PDMS. Inlet and outlet tubing was attached
to the vascular and alveolar layers using silicone glue.
The thickness of the membranes for each of the devices was measured
after the gas exchange testing by dividing the device in half and imaging
the cross-section of the membrane with light microscopy at 2003.
The membrane thicknesses were measured at 5 points across each device
and calculated by image analysis in Photoshop (Adobe Systems Inc,
San Jose, Calif).The Journal of Thoracic and CaGas Exchange Testing
An in vitro gas exchange test was developed to evaluate the potential of
the lung assist technology. The gas exchange test is similar to tests
performed by Page and colleagues12 and more recently by Lee and col-
leagues.13 A schematic of the test setup is shown in Figure 2. The test setup
consisted of a syringe pump (PHD 2000; Harvard Apparatus, Holliston,
Mass) that pumped 37C anticoagulated porcine blood (Lampire Biologics,
Pipersville, Pa) through the vascular chamber of the lung assist device at
flow rates of 0.6, 1.0, 2.0, 4.0, and 8.0 mL/min. Oxygen (100%; Air Gas,
Hingham, Mass) was delivered through the device at a flow rate of 400
mL/min. Blood and oxygen inlet pressures were measured using a pressure
transducer (Model PX209-30V15G5V; Omega Engineering, Stamford,
Conn) connected to a digital display (Model DPi8-EI, Omega Engineering).
For each device, blood was sampled before and after flowing through the
device to determine baseline and post-device blood gas values. Four devices
were tested in each of the 3 membrane types. Blood gas values (PO2, PCO2,
HCO3,% hemoglobin saturation) were measured using an iSTAT portable
clinical analyzer with CG8þcartridges (Abbot Point of Care Inc, East Wind-
sor, NJ). Oxygen transfer14 and carbon dioxide transfer rates15 were calcu-
lated using established equations.
Statistical Analysis
Results are expressed as mean  standard deviation. The gas transfer
results were compared between groups using the Student t test.RESULTS
This vascular network design achieved a high degree of
density with a repeating design of 23 capillary-like modules
and interconnecting transit channels. The area of the entire
vascular network is 30.8 cm2, and the area of just the vascu-
lar channels is 18.0 cm2 with a resulting 58.4% of the area of
the vascular network comprising an actual channel. Low
capillary-like shear stresses were present in the capillary-
like portions over a range of flow rates. For the 4 mL/min
flow rate, the shear stress within the capillary-like channels
of the devices ranged from less than 1 to 26.6 dynes/cm2
(Figure 1, D).
The resistance of this initial vascular network was de-
signed for arterial input pressures and may be redesigned
to match the input pressures of its intended vascular connec-
tion (eg, the pulmonary artery). Accordingly, the blood inlet
pressure ranged from 19.8 mm Hg at 0.6 mL/min to 123.1
mm Hg at 8.0 mL/min. The oxygen inlet pressure averaged
4.75  0.9 mm Hg for all devices.
The devices were reliably fabricated with each of the
membrane types. The device units were tested as single units
consisting of a vascular network and an adjacent alveolar
chamber separated by a gas-permeable membrane. The
resulting membrane thicknesses are as follows, the porous
polycarbonate control membranes were 12 mm thick as mea-
sured by the manufacturer. The silicone-coated porous poly-
carbonate membranes were 15 2 mm thick with a resultant
3-mm thickness of the silicone portion. The thickness of the
silicone only membranes was 63  19 mm.
The blood used for the testing was stored in a hard plastic
container between being drawn and used for testing. This
resulted in the blood being similar in gas content to thatrdiovascular Surgery c Volume 140, Number 5 991
FIGURE 1. Design of vascular network-based lung assist device. A, Top view of branched vascular network design with single blood inlet and outlet. B,
Cross-sectional scanning electron microscope image of cut edge of device with silicone membrane. Velocity plot (C) and (D) shear stress plot from compu-
tational fluid dynamics analysis of capillary-like area of vascular network at blood flow rate of 4 mL/min.
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PO2 of the blood was 53  4.5 mm Hg, and the baseline
PCO2 of the blood was 86.9 5.3 mmHg. The oxygen trans-
fer in the devices increased with increasing blood flow for
the device over the range of blood flow rates is shown in
Figure 3. The carbon dioxide transfer also increased with in-
creasing flow over the range of flow rates for all of the mem-
branes except for the silicone membrane, which trended
lower at the higher flow rates shown in Figure 4. By using
the entire area of the vascular network, the oxygen and car-
bon dioxide gas exchange was 89.3 and 78.1 mL/min/m2,
respectively, at 4 mL/min blood flow in the device. These
values for oxygen and carbon dioxide exchange are similar
to hollow fiber-based oxygenators, including the Biolung16
(oxygen transfer rate 64 mL/min/m2) and the Ambulatory-
AVCO2R prototype17 (carbon dioxide transfer rate
84 mL/min/m2). The challenge in this technology is to cre-
ate high-density vascular networks with minimal total992 The Journal of Thoracic and Cardiovascular Surgscaffold material to maximize gas transfer area and mini-
mize overall size.
DISCUSSION
Ambulatory lung assist devices may offer patients with
end-stage lungdisease newclinical options, includinga bridge
to transplant or eventually a destination therapy. This article
describes a new architectural design for a lung assist device.
In this device, a branched vascular network divides blood
flow into many parallel capillary-like channels analogous to
the native lung architecture. A thin gas-permeable membrane
functions similar to the alveolar membrane of the lung to ef-
fect oxygen and carbon dioxide exchange with the alveolar
chamber. This approach hasmany theoretic benefits. The vas-
cular network can achieve physiologic blood flow, including
physiologic shear stress throughout the network, and thereby
minimize platelet activation and thrombus formation within
the device. The entire blood contact surface of the device isery c November 2010
FIGURE 2. Schematic of in vitro gas exchange testing setup. Blood was
pumped through vascular network using syringe pump and oxygen deliv-
ered through the alveolar chamber. Samples for blood gas analysis were
taken before (S1) and after (S2) the device to calculate the gas transfer rates.
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of plasma leakage during long-term implantation.14 The de-
vice is scalable by stacking layers of the device units consist-
ing of the vascular network and alveolar chamber. The
resulting device can be a single module of stacked units or
multiple modules arranged in parallel to achieve adequate
gas transfer for a range of patient needs.
In this study, the devices had effective gas transfer over
a wide range of flow rates. Both the oxygen and carbon di-
oxide transfer increased in a nearly linear fashion for each
of the membranes with increasing flow rate. The exception
was the silicone membrane where the carbon dioxide trans-
fer decreased at the higher flow rates; however, this was not
statistically significant. There was no difference between the
gas transfer of the 2 silicone-based membranes and the
control membrane used in this initial study. The standardFIGURE 3. Oxygen transfer in lung assist device over range of blood flow rates.
any of the flow rates.
The Journal of Thoracic and Cadeviation at the higher flow rates was large and may be min-
imized in the future by increasing the sample size.
Extrapolating the data of this experiment with single-layer
devices (joined vascular network and alveolar chamber) can
formulate a picture of an implantable adult lung assist device
that could be made by scaling up this technology. The
amount of CO2 removal required for an effective bridge to
transplant device is not known. For a device to remove
20% of baseline CO2 (50 mL/min), the device would require
357 layers (using a silicone-coated porous membrane and
flow rate of 4 mL/min) and would have a total surface area
of 0.64 m2. The device would require approximately 25%
of the cardiac output and could be expected to increase the
PO2 from 57 to 79 mm Hg.
With its current size, a 357-layer device would be more
than 20 cm tall and 6 3 12 cm in breadth and width. Al-
though this size is too large to be clinically useful, the size
will decrease significantly in future iterations of the technol-
ogy by decreasing the size of each layer throughmanufactur-
ing optimization and reducing the total number of layers
required. Decreasing the thickness of the membrane will
also decrease the total number of layers required.
In comparison, the Novalung assist device (Novalung
GmbH, Baden-Wu¨rttemberg, Germany) is currently clini-
cally available for peripheral placement principally as a ven-
tilatory support device.18,19 The arteriovenous placement of
the device limits oxygenation capacity but has excellent CO2
transfer capacity of 201.3 mL/min/2.20 This therapy requires
full anticoagulation and uses a traditional hollow fiber archi-
tecture.
In this study, there were no significant differences in gas
exchange between the 2 plasma-impermeable membranes,There was no statistically significance difference between the membranes at
rdiovascular Surgery c Volume 140, Number 5 993
FIGURE 4. Carbon dioxide transfer in lung assist device over range of blood flow rates. There was no statistically significance difference between the mem-
branes at any of the flow rates.
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other study, a significant gas transfer differencewas noted be-
tween silicone coating (0.2 mm coating) on a microporous
hollow fiber oxygenator and a silicone fiber oxygenator
(100 mm wall).14 In contrast, the membranes used in this
study were approximately 40% thinner at 63 mm, whereas
the silicone coating on the porous membranes was substan-
tially thicker at 3 mm. Both silicone and silicone-coated po-
rous membranes can be optimized, warranting further
investigation of each to determine which may be the best op-
tion. Increasing the porosity of the sheet-based microporous
membrane and minimizing the silicone coating thickness by
using plasma polymerization or chemical vapor deposition
may be ways of optimizing the gas permeability of the
silicone-coated porous membrane. For the silicone-only
membrane, the siliconemembrane thickness may be reduced,
and one can expect a corresponding linear increase in gas
transfer. We expect that a silicone membrane thickness of
less than 10 mm is possible using this architectural approach.
Although the gas transfer increase is linear with increas-
ing flow rate for each of the membranes, it does not double
with the flow rate. Thus, there is a loss of efficiency of gas
exchange with increasing flow rates. The central difference
between the native lung and this first-generation vascular
network device (and hollow fiber oxygenators) is the size
of the blood channels versus native lung capillaries. It is ex-
pected that this difference accounts for loss of gas exchange
efficiency as flow rate increases. Hollow fiber oxygenators
have diffusion distances on the order of 200 to 300 mm,21
and the channels in this device are 200 mm deep while
a native capillary is 5 to 10 mm in diameter. Page and
colleagues12 described the kinetics associated with oxygen994 The Journal of Thoracic and Cardiovascular Surgtransport in capillaries and showed that full saturation of
the hemoglobin in a 25-mm diameter capillary takes approx-
imately 4 times as long in a 10-mm diameter capillary.12 The
channels in this vascular network are larger than the 25 mm
used by Page and colleagues and are comparable to tradi-
tional oxygenators. There is significant shunting of blood
at higher flow rates and a decrease in the efficiency of gas
transfer. This can be improved by minimizing the diameter
of the smallest capillary-like channels and increasing mem-
brane permeability. Lee and colleagues21 have begun to
build on the work by Page and colleagues to optimize the
balance of channel depth, blood velocity, and membrane
permeability. Further work in this area is required to opti-
mize gas exchange of these channel-based networks.
As channel diameters are decreased to improve gas ex-
change, the risk of thrombosis increases. Continued refine-
ment of the design of the vascular network to achieve
physiologic shear stress and minimal flow disturbances
within the network is paramount. Because these vascular net-
works are designed to mimic native blood vessels, they may
be endothelialized to greatly reduce the risk of thrombus.
This would require a different scaffold material but has
been demonstrated in principle by our group22 and others.23
The central limitation of the initial testing of this device is
the small overall size of the device tested. Development of
a scaled-up clinically sized device is an important next
step in validating this technology. High oxygen flow rates
were used in this initial evaluation; however, it is expected
that much lower oxygen flow rates will affect similar gas
transfer. Variation in the oxygen flow rates is a principle el-
ement of the next step in testing. Similarly, demonstrating
the effectiveness of the device in a small animal model isery c November 2010
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change function. The durability of the device with regard
to supporting blood flow for an extended period of time
will need to be assessed in vivo. The devices have supported
sustained blood flow for hours in vitro with pressures ex-
ceeding 120 mm Hg, but longer term durability has not
been assessed. Although the blood flow is more physiologic
than hollow fiber-based devices, some level of anticoagula-
tion will be required for this device without endothelial cells.
The exact level of anticoagulation required will need to be
assessed with in vivo studies.
CONCLUSIONS
A new architectural approach toward creating a lung assist
device based on a bifurcated vascular network has been de-
veloped. Initial testing using silicone and silicone-coated mi-
croporous membranes demonstrate gas transfer of oxygen
and carbon dioxide similar to existing hollow fiber oxygen-
ators when normalizing by surface area. Optimization of this
technology will focus on increasing the permeability of the
gas transfer membrane and decreasing the diameter of the
vascular network channels while optimizing physiologic
blood flow.
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for scanning electron microscope imaging assistance.
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